Diabetes, Vol 42, Issue 10 1407-1414, Copyright © 1993 by American Diabetes Association

ARTICLES

Metabolism of des(64,65)-human proinsulin in the rat. Evidence for the proteolytic processing to insulin

VJ Wroblewski, M Masnyk and RE Kaiser
Department of Drug Metabolism and Disposition, Lilly Research Laboratories, Division of Eli Lilly and Company, Indianapolis, Indiana.

The metabolism of des(64,65)-human proinsulin was examined in rats after subcutaneous administration. Profiles of circulating insulin-like immunoreactivity in rat plasma 25 min after subcutaneous administration were evaluated by anion exchange fast protein liquid chromatography and reversed-phase high-performance liquid chromatography. Both techniques indicated the presence of circulating immunoreactivity having retention characteristics of human insulin. This metabolite peak comprised 5-10% of circulating immunoreactivity; the remainder had retention characteristics of des(64,65)-human proinsulin. The peaks of immunoreactive material were isolated and their structure determined using reversed-phase high-performance liquid chromatography and electrospray ionization mass spectrometry. The major circulating component co-eluted with des(64,65)-human proinsulin and had an identical mass spectrum. Two circulating metabolites were identified. These metabolites co-eluted by reversed-phase high-performance liquid chromatography with human insulin and diarginyl(B31,32)-human insulin and had mass spectra identical to the standard compounds. The data indicate proteolytic processing of des(64,65)-human proinsulin involves an initial tryptic cleavage at the carboxy side of ArgB32, with the formation of human insulin by the subsequent action of a carboxypeptidase to remove the ArgB31-ArgB32 dipeptide from diarginyl(B31,32)-human insulin. The results suggest that some of the pharmacological activity of des(64,65)-human proinsulin may be mediated in part by circulating insulin-like metabolites.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. J. Wroblewski, C. McCloud, K. Davis, J. Manetta, R. Micanovic, and D. R. Witcher Pharmacokinetics, Metabolic Stability, and Subcutaneous Bioavailability of a Genetically Engineered Analog of DcR3, FLINT [DcR3(R218Q)], in Cynomolgus Monkeys and Mice Drug Metab. Dispos., April 1, 2003; 31(4): 502 - 507. [Abstract] [Full Text] [PDF]

				X. Zhu, L. Orci, R. Carroll, C. Norrbom, M. Ravazzola, and D. F. Steiner Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3 PNAS, August 6, 2002; 99(16): 10299 - 10304. [Abstract] [Full Text] [PDF]

				M. Furuta, R. Carroll, S. Martin, H. H. Swift, M. Ravazzola, L. Orci, and D. F. Steiner Incomplete Processing of Proinsulin to Insulin Accompanied by Elevation of Des-31,32 Proinsulin Intermediates in Islets of Mice Lacking Active PC2 J. Biol. Chem., February 6, 1998; 273(6): 3431 - 3437. [Abstract] [Full Text] [PDF]